Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
Megan E. B. Clowse(Duke University), C. Stach(Merck KGaA, Darmstadt (Germany)), C. Michael Neuwelt, Caroline Gordon(University of Birmingham), Kathryn Hobbs(University of Kentucky), C. Galateanu(UCB Pharma (Belgium)), Sabine Bongardt(UCB Pharma (Germany)), B. Kilgallen(UCB Pharma (United States)), Daniel J. Wallace(Cedars-Sinai Medical Center), Richard Furie(Hofstra University), Michelle Petri(Johns Hopkins University), Carolyn Beaudot(UCB Pharma (United States)), Liliana Duca, Piotr Leszczyński(Poznan University of Medical Sciences), Marilyn C. Pike(Bethesda Hospital), Kenneth Kalunian(University of California, San Diego), Mauro Waldemar Keiserman(Pontifícia Universidade Católica do Rio Grande do Sul)
Cited by 237
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840